Evidence map›Paper›PMID 41683580›Full record

ReviewInternational journal of molecular sciences2026

Targeting ATR-CHK1 and ATM-CHK2 Axes in Pancreatic Cancer-A Comprehensive Review of Literature.

Mateusz Kciuk, Katarzyna Wanke, Beata Marciniak, Damian Kołat, Marta Aleksandrowicz, Somdutt Mujwar, Tarik Ainane, Renata Kontek

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Diagnostics (Basel, Switzerland) · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mateusz KciukDepartment of Molecular Biotechnology and Genetics, University of Lodz, 90-237 Lodz, Poland.ORCID 0000-0002-8616-3825
Katarzyna WankeDepartment of Molecular Biotechnology and Genetics, University of Lodz, 90-237 Lodz, Poland.ORCID 0009-0000-9010-8493
Beata MarciniakDepartment of Molecular Biotechnology and Genetics, University of Lodz, 90-237 Lodz, Poland.
Damian KołatDepartment of Molecular Biotechnology and Genetics, University of Lodz, 90-237 Lodz, Poland.ORCID 0000-0002-1086-3796
Marta AleksandrowiczLaboratory of Preclinical Research and Environmental Agents, Mossakowski Medical Research Institute, Polish Academy of Sciences, 5 A. Pawińskiego Street, 02-106 Warsaw, Poland.ORCID 0000-0003-1922-7662
Somdutt MujwarChitkara College of Pharmacy, Chitkara University, Rajpura 140401, Punjab, India.ORCID 0000-0003-4037-5475
Tarik AinaneSuperior School of Technology of Khenifra, University of Sultan Moulay Slimane, P.O. Box 170, Khenifra 54000, Morocco.ORCID 0000-0001-6743-2666
Renata KontekDepartment of Molecular Biotechnology and Genetics, University of Lodz, 90-237 Lodz, Poland.ORCID 0000-0003-2859-9839

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer (PC) remains a highly lethal malignancy with limited treatment options and poor survival. Targeting DNA damage response (DDR) pathways has emerged as a promising therapeutic strategy, particularly the ATR-CHK1 and ATM-CHK2 axes. Preclinical studies demonstrate that ATR inhibition disrupts replication stress tolerance, impairs homologous recombination, and disables checkpoint control, enhancing cytotoxicity from standard therapies including gemcitabine, FOLFIRINOX, fluoropyrimidines, and radiotherapy. Synergistic effects have also been observed with other DDR-targeted agents, such as PARP and WEE1 inhibitors. Genomic contexts, including

Indexed as

Ataxia Telangiectasia Mutated ProteinsCheckpoint Kinase 1Checkpoint Kinase 2Pancreatic NeoplasmsAnimalsDNA DamageHumansMolecular Targeted TherapyProtein Kinase InhibitorsSignal TransductionAtaxia Telangiectasia Mutated ProteinsATM protein, humanATR protein, humanCheckpoint Kinase 1Checkpoint Kinase 2CHEK1 protein, humanCHEK2 protein, humanProtein Kinase Inhibitorscell cycle checkpointcombination regimensDNA damageDNA damage response (DDR)immunotherapypancreatic ductal adenocarcinoma (PDAC)precision medicine

Identifiers

PMID41683580
PMCPMC12898043

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.